179 related articles for article (PubMed ID: 33888093)
21. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
[TBL] [Abstract][Full Text] [Related]
22. Validation of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.
Burgers LE; Siljehult F; Ten Brinck RM; van Steenbergen HW; Landewé RBM; Rantapää-Dahlqvist S; van der Helm-van Mil AHM
Rheumatology (Oxford); 2017 Dec; 56(12):2123-2128. PubMed ID: 28968699
[TBL] [Abstract][Full Text] [Related]
23. Databases of patients with early rheumatoid arthritis in the USA.
Sokka T; Willoughby J; Yazici Y; Pincus T
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
[TBL] [Abstract][Full Text] [Related]
24. Case finding for population-based studies of rheumatoid arthritis: comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis.
Liu H; Harker JO; Wong AL; Maclean CH; Bulpitt KJ; Mittman BS; Fitzgerald J; Grossman J; Rubenstein LZ; Hahn B; Paulus HE; Kahn KL
Semin Arthritis Rheum; 2004 Apr; 33(5):302-10. PubMed ID: 15079761
[TBL] [Abstract][Full Text] [Related]
25. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
26. Disease activity, treatment and long-term prognosis of adult juvenile idiopathic arthritis patients compared with rheumatoid arthritis patients.
Matsumoto T; Matsui T; Hirano F; Tohma S; Mori M
Mod Rheumatol; 2020 Jan; 30(1):78-84. PubMed ID: 30499364
[No Abstract] [Full Text] [Related]
27. Dose down-titration of biological disease-modifying antirheumatic drugs in daily clinical practice: Shared decision-making and patient treatment preferences in Japanese patients with rheumatoid arthritis.
Komiya T; Takase-Minegishi K; Sakurai N; Nagai H; Hamada N; Soejima Y; Sugiyama Y; Tsuchida N; Kunishita Y; Kishimoto D; Kobayashi K; Kamiyama R; Yoshimi R; Kirino Y; Ohno S; Nakajima H
Int J Rheum Dis; 2019 Nov; 22(11):2009-2016. PubMed ID: 31515933
[TBL] [Abstract][Full Text] [Related]
28. [Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons].
Albrecht K; Luque Ramos A; Callhoff J; Hoffmann F; Minden K; Zink A
Z Rheumatol; 2018 Mar; 77(2):102-112. PubMed ID: 28324149
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014.
Hunter TM; Boytsov NN; Zhang X; Schroeder K; Michaud K; Araujo AB
Rheumatol Int; 2017 Sep; 37(9):1551-1557. PubMed ID: 28455559
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of chronic kidney disease and administration of RA-related drugs in patients with RA: The NinJa 2012 study in Japan.
Saisho K; Yoshikawa N; Sugata K; Hamada H; Tohma S
Mod Rheumatol; 2016; 26(3):331-5. PubMed ID: 26374955
[TBL] [Abstract][Full Text] [Related]
31. Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis.
Salaffi F; Di Carlo M; Vojinovic J; Tincani A; Sulli A; Soldano S; Andreoli L; Dall'Ara F; Ionescu R; Simić Pašalić K; Balčune I; Ferraz-Amaro I; Tlustochowicz M; Butrimienė I; Punceviciene E; Toroptsova N; Grazio S; Morović-Vergles J; Masaryk P; Otsa K; Bernardes M; Boyadzhieva V; Cutolo M
Joint Bone Spine; 2018 May; 85(3):317-322. PubMed ID: 28549945
[TBL] [Abstract][Full Text] [Related]
32. Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative-a rheumatoid arthritis cohort.
Movahedi M; Cesta A; Li X; Bombardier C;
J Clin Epidemiol; 2019 Oct; 114():95-103. PubMed ID: 31226411
[TBL] [Abstract][Full Text] [Related]
33. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study.
Kato E; Sawada T; Tahara K; Hayashi H; Tago M; Mori H; Nishino J; Matsui T; Tohma S
Int J Rheum Dis; 2017 Jul; 20(7):839-845. PubMed ID: 28205423
[TBL] [Abstract][Full Text] [Related]
34. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
35. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years.
Aletaha D; Eberl G; Nell VP; Machold KP; Smolen JS
Ann Rheum Dis; 2002 Jul; 61(7):630-4. PubMed ID: 12079906
[TBL] [Abstract][Full Text] [Related]
36. Rheumatology practice in Japan: challenges and opportunities.
Oku K; Atsumi T
Rheumatol Int; 2019 Sep; 39(9):1499-1505. PubMed ID: 30888472
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
Crane MM; Juneja M; Allen J; Kurrasch RH; Chu ME; Quattrocchi E; Manson SC; Chang DJ
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1646-55. PubMed ID: 26097059
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
39. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
40. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
